Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 8076

Next Previous
X
Search
Drug Profile

AZD 8076

Alternative Names: AZD-8076

Latest Information Update: 23 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer AstraZeneca; Inovio Pharmaceuticals
  • Class Antivirals; COVID-19 vaccines; DNA; DNA vaccines; Monoclonal antibodies; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I COVID 2019 infections

Most Recent Events

  • 20 Jun 2022 AstraZeneca, Inovio Pharmaceuticals, Indiana University, University of Pennsylvania, and the Wistar Institute enters into RnD agreement for development of DNA encoded monoclonal antibodies
  • 14 Jun 2022 Phase-I clinical trials in COVID-2019 infections (In the elderly, Prevention, In adults) in USA (IM) (NCT05293249)
  • 09 Jun 2022 Preclinical trial in COVID-2019 infections in USA (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top